Quick Answer
Allogene Therapeutics, Inc. reported Operating Income of -$209.31 million for fiscal year 2025.
Allogene Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$209.31M | +23.4% |
| 2024 | -$273.20M | +16.6% |
| 2023 | -$327.74M | +2.3% |
| 2022 | -$335.54M | -86.2% |
| 2021 | -$180.19M | +30.2% |
| 2020 | -$258.24M | -27.8% |
| 2019 | -$202.01M | -4.8% |
| 2018 | -$192.84M | -9642000.0% |
| 2017 | -$2.0K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$44.90M | +37.4% | +21.0% |
| June 30, 2025 | -$56.82M | +20.5% | +12.8% |
| March 31, 2025 | -$65.19M | +6.2% | +9.2% |
| September 30, 2024 | -$71.77M | -13.9% | -0.5% |
| June 30, 2024 | -$71.43M | +11.3% | -2.8% |
| March 31, 2024 | -$69.50M | +29.9% | -10.3% |
| September 30, 2023 | -$63.00M | +23.6% | +21.8% |
| June 30, 2023 | -$80.54M | -5.2% | +18.7% |
- Allogene Therapeutics, Inc. showed an increase of +23.4% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, Allogene Therapeutics, Inc.’s operating income has declined by 10465650.0% (from -$2.0 thousand to -$209.31 million).
- The most recent figure is from Allogene Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: